Navigation Links
Gaining ground in the race against antibiotic resistance

Antibiotic resistance has put humans in an escalating 'arms race' with infectious bacteria, as scientists try to develop new antibiotics faster than the bacteria can evolve new resistance strategies. But now, researchers have a new strategy that may give them a leg up in the race -- reproducing in the lab the natural evolution of the bacterial enzymes that confer resistance.

A team of scientists in Argentina and Mexico identified mutations that increased the efficiency of a bacterial enzyme that renders penicillin and cephalosporin antibiotics useless. The results could lead to more effective enzyme inhibitors by giving drug designers a sneak peek at the next generation of resistance.

Alejandro Vila, a Howard Hughes Medical Institute international research scholar, and colleagues at the University of Rosario's Institute of Molecular and Cellular Biology in Argentina and at the Biotechnology Institute of the National Autonomous University of Mexico report their findings in the early online edition of the Proceedings of the National Academy of Sciences the week of September 19, 2005.

Staying one step ahead of resistance with new antibiotics and treatments for infections is a huge challenge because bacteria evolve quickly to evade them. When the scientists introduced random mutations into the gene for a bacterial resistance enzyme and grew the bacteria on increasing concentrations of antibiotics, it took only a few days of test tube evolution to increase drug resistance. Eventually, they found four mutations in the evolved enzyme that allowed the bacteria to survive on a drug dose 64 times higher than the dose that kills bacteria hosting the un-evolved enzyme.

"We were mimicking what is going on in the doctor's clinic -- putting selection pressure on the enzyme by giving higher doses of antibiotic," said Vila. "The only ones to survive will be those that have an enzyme that can work more efficiently."

The researchers conducted
'"/>

Source:Howard Hughes Medical Institute


Page: 1 2 3

Related biology news :

1. Prescription Drug Patches Gaining Ground, Tackling New Therapies
2. What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brains Internal Clock
3. Anti-cancer Compound In Beer Gaining Interest
4. HIV vaccine trial breaks ground for future research
5. Roots Engage in Underground Chemical Warfare
6. Underground tunnels discovered as means for communication between immune system cells
7. Huntingtons cure in flies lays groundwork for broader treatment approaches
8. UQ scientists break new ground in fight against infection & chronic disease
9. Bugs expose underground carbon traffic system 10 times more important than fossil fuel burning
10. Saharas edge studied from ground, air and space to improve water management
11. Bones from blood: Scientists aim to break new ground on fractures

Post Your Comments:
(Date:11/24/2009)...ntarctica has long held secrets of the earth,s his... there has been very little information on the env...ce for millions of years. Now, a team of researche...n funded to the tune of $10 million dollars by the...e bottom of things literally. These scientists wi...
(Date:11/23/2009)... The community-associated strain of the deadly su... to most common antibioticsposes a far greater hea... way into hospitals, according to a study in the D..., The new threat is easily picked up in fitness ...increased the overall burden of MRSA within hospit...
(Date:11/23/2009)...Current research suggests that a common oral bacte...ed report by Nichols et al, "Unique Lipids from a ...R2 Ligands Capable of Enhancing Autoimmunity," app...ournal of Pathology . , Multiple sclerosis (MS),...in and spinal cord, affects nearly 1 in 700 people...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Authentidate Holding Corp to Report Fourth Quarter and Fiscal Year End 2009 Results on Thursday September 24 2009 56739 1Authentidate Holding Corp to Report Fourth Quarter and Fiscal Year End 2009 Results on Thursday September 24 2009 56739 2Abaxis Inc to Present at the ThinkEquity Sixth Annual Growth Conference 56737 1PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 1PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 2PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 3PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 4PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 5PTC Therapeutics Initiates Registration Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 13969 6
...e and then presented with a chemoattractant signal... a polarized morphology and aggregate to form a mi...pmental program that culminates in the formation o...w this streaming response is coordinated at a sing... Journal of Cell Biology ( www.jcb.org ). , Bes...
... chest wall deformity known as pectus excavatum co...exercise, according to a study published December ...ed at 11 North American hospitals, involved teleph...he ages of 8 and 21 who had pectus excavatum surge...he results were dramatic. Patients reported greatl...
...ant that has a potent effect on gene activity, cou...n the December issue of BioScience . The chemical...d and textile preservative, and as a pesticide on ...ns. , Tributyltin affects sensitive receptors in ...at very low concentrationsa thousand times lower t...
Other Biology News:Marked improvement in body image, physical stamina, post-surgical pectus patients report 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 3Persistent pollutant may promote obesity 2
(Date:11/24/2009)... The FBI recently approved t...atories participating in or generating DNA records... Madison, WI USA (PRWEB) -- The FBI re...System for use by laboratories participating in, ...dex System (NDIS). NDIS currently contains more th...
(Date:11/24/2009)..., TSXVENTURE:HTL , TORONTO,Nov.24/PRNewswi...lyCalottoCapitalInc.,aleadingproviderofadvancedlas...rtilityclinicmarkets,todayreportedoperationalandfi...009. , ,Q32009Highlights,-Revenuewas$1.46million...nwas66.3percentcomparedwith66.1percentinQ3,2008,-N...
(Date:11/24/2009)..., SANDIEGO,Nov.24,2009/PRNewswire-FirstCall/--A...todaythatthecompanyisscheduledtopresentatthePiperJ...09at11:30a.m.EasternTime(8:30a.m.PacificTime)atthe...resident andChiefExecutiveOfficer,isscheduledtopro...elopmentanddiscoveryprograms. ,, Aliveaudiowebc...
(Date:11/24/2009)..., BOZEN,Italy,November24/PRNewswire/--HealthRob...ntventurewithagroupofselected,investors.Thisrecent...meHealthRoboticsCanada,Inc.andwillmarket,install,a...t,whichincludesthe,revolutionaryproductofferingsi....icsCanadaInc.willalsoprovideassistanceonan"asneede...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...any health plans are moving to in-source Disease M... costs and improve member outcomes , , , ,...nagement Solution(IHMS) platform fully integrates ... , , , , , , Blue Cross Blue Shi...to improve care and manage members, healthcare mor...
...., Feb. 2 MannKind Corporation (Nasdaq: MNKD ),...izing treatments for diabetes and cancer, announce...otechnology Industry Organization BIO CEO & In...:15 PM (EST) at the Hilton Waldorf Astoria in New ... Company will host a breakfast meeting for invited...
...ruary 2 Axentis Pharma AG is to present its,recen...apeutic formulation,for treating chronic lung dise...rum in Zurich, Switzerland. This invited talk come...present its recent achievements at the Biotech,Sho...any,s ongoing success,story is a recent capital in...
Other Biology Technology:Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 2Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 3Alere Offers Single-Source Solution for Health Plans Seeking to In-Source Health Management Programs 4MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 2Chronic Lung Disease - Axentis Pharma Attracts Investment Interest 3
Newborn Calf Serum from Lifeblood Medical, Inc.
Normal Calf Serum from Equitech-Bio
Custom DNA Primers from Invitrogen
Direct ELISA Assay Diluent from BioFX Laboratories, Inc.
Biology Products: